$3.90
5.11% today
Nasdaq, May 13, 06:05 pm CET
ISIN
US51654W1018
Symbol
LTRN
Sector
Industry

Lantern Pharma Inc Stock price

$4.11
+0.58 16.43% 1M
+0.53 14.80% 6M
+0.92 28.84% YTD
-1.98 32.51% 1Y
-0.91 18.13% 3Y
-10.84 72.51% 5Y
-10.84 72.51% 10Y
Nasdaq, Closing price Mon, May 12 2025
+0.13 3.27%
ISIN
US51654W1018
Symbol
LTRN
Sector
Industry

Key metrics

Market capitalization $44.33m
Enterprise Value $20.56m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 2.09
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-22.22m
Free Cash Flow (TTM) Free Cash Flow $-17.83m
Cash position $24.01m
EPS (TTM) EPS $-1.93
P/E forward negative
Short interest 2.67%
Show more

Is Lantern Pharma Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,793 stocks worldwide.

Lantern Pharma Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

2 Analysts have issued a Lantern Pharma Inc forecast:

2x Buy
100%

Analyst Opinions

2 Analysts have issued a Lantern Pharma Inc forecast:

Buy
100%

Financial data from Lantern Pharma Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
- -
-
100%
- Direct Costs 0.19 0.19
12% 12%
-
-0.19 -0.19
12% 12%
-
- Selling and Administrative Expenses 5.71 5.71
1% 1%
-
- Research and Development Expense 16 16
36% 36%
-
-22 -22
24% 24%
-
- Depreciation and Amortization 0.19 0.19
12% 12%
-
EBIT (Operating Income) EBIT -22 -22
24% 24%
-
Net Profit -21 -21
30% 30%
-

In millions USD.

Don't miss a Thing! We will send you all news about Lantern Pharma Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Lantern Pharma Inc Stock News

Neutral
Business Wire
one day ago
DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (Nasdaq: LTRN), an artificial intelligence company developing targeted and transformative cancer therapies using its proprietary AI platform, RADR®, today announced that the U.S. Food and Drug Administration (FDA) has cleared the amendment to its Investigational New Drug (IND) application to initiate a Phase 1b/2 clinical trial of LP-184 in a genomic...
Neutral
Business Wire
5 days ago
DALLAS--(BUSINESS WIRE)--Q1 Earnings Call Save The Date.
Neutral
Business Wire
8 days ago
DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (Nasdaq: LTRN), an artificial intelligence company developing targeted and transformative cancer therapies using its proprietary AI platform, RADR®, today announced that it has received clearance of its Investigational New Drug Application (IND) from the U.S. Food and Drug Administration (FDA) for a Phase 1b/2 clinical trial for LP-184 in Triple Nega...
More Lantern Pharma Inc News

Company Profile

Lantern Pharma Inc., a clinical stage biotechnology company, focuses on leveraging artificial intelligence (A.I.), machine learning, and genomic data to streamline the drug development process. Its advanced drug candidate is LP-100, which is in phase II clinical trials to treat metastatic, castration-resistant, prostate cancer. The company also develops LP-300 as a combination therapy for female non or never-smokers with non-small cell lung cancer adenocarcinoma. In addition, its preclinical development drug candidate is LP-184, a non-hormone, non-chemotherapy, next generation alkylating agent with nanomolar potency that damages DNA in cancer cells that overexpress certain biomarkers indicated primarily in solid tumors, such as those in prostate and ovarian cancers. The company was incorporated in 2013 and is based in Dallas, Texas.

Head office United States
CEO Panna Sharma
Employees 24
Founded 2013
Website www.lanternpharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today